Fallopian tube malignant mixed müllerian tumor (carcinosarcoma): A case report with immunohistochemical profiling

European Journal of Gynaecological Oncology

Volumn 29, Issue 5, 2008, Pages 538-542

  Kourea, H P ^a   Adonakis, G ^a   Androutsopoulos, G ^a   Zyli, P ^a   Kourounis, G ^a   Decavalas, G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Carcinosarcoma; Fallopian tube; Immunohistochemistry; Malignant mixed m llerian tumor (MMMT); WT1

Indexed keywords

CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CISPLATIN; CK8 ANTIGEN; CYTOKERATIN AE3; DESMIN; DOXORUBICIN; HBME ANTIGEN; HHF35 ANTIGEN; MYOD1 PROTEIN; MYOGENIN; PACLITAXEL; PROTEIN P53; SMA ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIMENTIN; WT1 PROTEIN;

ABDOMINAL HYSTERECTOMY; ABDOMINAL PAIN; ADNEXA DISEASE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CARCINOMA IN SITU; CASE REPORT; CLINICAL FEATURE; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIXED MULLERIAN TUMOR; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

AGED; ANTIGENS, CD56; ANTIGENS, CD57; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CARCINOSARCOMA; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 54949106147     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Carlson J.A., Ackerman B.L., Wheeler J.E.: "Malignant mixed müllerian tumor of the fallopian tube". Cancer, 1993, 71, 187.
2. Scully R.E., Young R.H., Clement P.B.: "Tumors of the fallopian tube: Histologic classification and cancer staging epithelial and mixed epithelial-mesenchymal tumors". In: Rosai J., Sobin L.H. (eds.). Atlas of Tumor Pathology: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Third series. Armed Forces Institute of Pathology, Washington, D.C., 1998, 457.
3. Saleh E.R.M., Franca C.M., Marques M.M.: "Neural adhesion molecule (N-CAM) in pleomorphic adenoma and carcinoma expleomorphic adenoma". J. Oral. Pathol. Med., 2003, 32, 562.
4. George E., Manivei C., Dehner L.P., Wick M.R.: "Malignant mixed müllerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation". Hum. Pathol., 1991, 21, 215.
5. Amant F., Moerman P., Davel G.H., De Vos R., Vergote I., Lindesque B.G., de Jonge E.: "Uterine carcinosarcoma with melanocytic differentiation". Int. J. Gynecol. Pathol., 2001, 20, 186.
6. Kuroda N., Moriki T., Oguri H., Maeda N., Toi M., Miyazaki E. et al.: "Malignant mixed müllerian tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells". APMIS, 2005, 113, 643.
7. Alvarado-Cabrero I., Cheung A., Caduff R.: "Tumors of the fallopian tube". In: Tavassoli F.A., Devilee P. (eds.). World Health Organization Classification of Tumours. Pathology and Genetics: Tumors of the Breast and female genital organs. Lyon, France, IARC Press, 2003, 210.
8. Costa M.J., Vogelsan J., Young L.J.: "p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases". Mod. Pathol., 1994, 7, 619.
9. Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., Finkelstein S.D.: "Carcinosarcomas (malignant mixed müllerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components". Hum. Pathol., 1998, 29, 82.
10. Pritchard-Jones K., Fleming S., Davidson D., Bickmore W., Porteus D., Bard J. et al.: "The candidate Wilm's tumour gene is involved in the genitourinary development". Nature, 1990; 346:194-197.
11. Amin K.M., Litzky L.A., Smythe W.R., Mooney A.M., Morris J.M. et al.: "Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma". Am. J. Pathol., 1995, 146, 344.
12. Acs G., Pasha T., Zhang P.J.: "WT1 is differentially expressed in serous endometrioid clear cellvand mucinous carcinomas of the peritoneum, fallopian tube, ovary and endometrium". Int. J. Gynecol. Pathol., 2004, 23, 110.
13. Kumar-Singh S., Segers K., Rodeck U., Backhovens H., Bogers J., Weyler J. et al.: "WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis". J. Pathol., 1997, 181, 67.
14. Kourea H.P., Cordon-Cardo C., Dudas M., Leung D., Woodruff J.M.: "Expression of p27/kip and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas. The emerging role of p27 in malignant transformation of neurofibromas". Am. J. Pathol., 1999, 155, 1885.
15. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D. et al.: "Cytoplasmic relocalization and inhibition of cyclin-dependent kinase inhibitor p27(kip1) by PKB/Akt-mediated phosphorylation in breast cancer". Nat. Med., 2002, 8, 1136.